drugset
drugset / Trial / NCT01576367

Efficacy, Safety and Tolerability of ACZ885 in Pediatric Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease

NCT01576367 ↗

Phase 3 Completed 17 enrolled Novartis Pharmaceuticals
Non-randomizedSingle-groupTreatment

Summary

This trial will provide long-term safety, efficacy and tolerability of ACZ885 in CAPS patients that completed the CACZ885D2307 study

Timeline

Start
2012-01-16
Primary completion
2015-10-13
Completion
2015-10-13

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Canakinumab Monoclonal antibody 2 mg/kg Subcutaneous
Subject Canakinumab Monoclonal antibody 4 mg/kg Subcutaneous
Subject Canakinumab Monoclonal antibody 6 mg/kg Subcutaneous
Subject Canakinumab Monoclonal antibody 8 mg/kg Subcutaneous

Indications

CINCA syndrome Muckle-Wells syndrome familial cold autoinflammatory syndrome